Fornaro L, Caparello C, Vivaldi C, Rotella V, Musettini G, Falcone A, Baldini E, Masi G. Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review. World J Gastroenterol 2014; 20(20): 6081-6091 [PMID: 24876730 DOI: 10.3748/wjg.v20.i20.6081]
Corresponding Author of This Article
Dr. Lorenzo Fornaro, Division of Medical Oncology, Azienda USL2 Lucca, Via dell’Ospedale 1, 55100 Lucca, Italy. lorenzo.fornaro@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
XELOX + BV for 3 cycles, then XELOX for 1 cycle, CT-RT in case of PD
Intermediate-risk T3
Three patients (not specified)
15%
Table 5 Main ongoing trials with bevacizumab in locally-advanced rectal cancer
Study
Design
n
Pre-operative treatment
RT
Primary endpoint
Status
Comments
AXE BEAM trial (NCT00828672)
Randomized
80
Concomitant XELOX +/- BV + RT
CT-RT
pCR
Recruiting
Phase II
45 Gy
New Beat trial (NCT01554059)
Phase II
28
Concomitant FOLFOX + BV + RT
CT-RT
pCR
Recruiting
40 Gy/20 fractions
NCT01818973
Phase II
45
XELOX + BV for 1 cycle followed by concomitant CT-RT with XELOX + BV for 2 cycles and RT
CT-RT
Tumor regression grade
Recruiting
Adjuvant CT with XELOX for 3 cycles followed by capecitabine for 2 cycles
50 Gy/25 fractions
BACCHUS trial (NCT01650428)
RandomizedPhase II
60
FOLFOX + BV for 5 cycles followed by FOLFOX for 1 cycle vs FOLFOXIRI + BV for 5 cycles followed by FOLFOXIRI for 1 cycle
No
pCR
Recruiting
Magnetic resonance imaging-defined poor risk criteria
NCT01871571
Phase II
43
mFOLFOX7 + BV for 6 cycles
No
pCR
Recruiting
NCT00865189
Randomized Phase II
91
FOLFOX + BV for 6 cycles followed by CT-RT with BV and 5-FU vs CT-RT alone
CT-RT
pCR
Ongoing, not recruiting
Not specified RT dose and fractioning
NCT00462501
Phase II
36
FOLFOX + BV for 4 cycles followed by FOLFOX for 2 cycles with selective use of CT-RT with 5-FU in patients not candidate for R0 resection
CT-RT
R0 resection rate
Ongoing, not recruiting
Not specified RT dose and fractioning
TRUST trial (EUDRACT 2011-003340-45)
Phase II
43
FOLFOXIRI + BV for 6 cycles followed by CTRT with BV and capecitabine or 5-FU
CT-RT 50.4 Gy/28 fractions
DFS rate at 2 yr
Recruiting
Citation: Fornaro L, Caparello C, Vivaldi C, Rotella V, Musettini G, Falcone A, Baldini E, Masi G. Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review. World J Gastroenterol 2014; 20(20): 6081-6091